Shaw Maddison, Alves Andrew, Lye Jessica, Lehmann Joerg, Kadeer Fayz, Beveridge Sabeena, Hardcastle Nicholas, Geso Moshi, Brown Rhonda
Australian Clinical Dosimetry Service, Australian Radiation Protection and Nuclear Safety Agency, Melbourne, Australia.
School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia.
J Appl Clin Med Phys. 2025 Jul;26(7):e70133. doi: 10.1002/acm2.70133. Epub 2025 Jun 5.
To create and conduct a comprehensive onsite end-to-end dosimetry audit to assess treatment accuracy of spine, lung, and soft tissue Stereotactic Body Radiotherapy (SBRT) across Australian and New Zealand (ANZ) radiotherapy centers.
The Australian Clinical Dosimetry Service (ACDS) anthropomorphic thorax phantom underwent a CT scan, planning, and treatment delivery according to local techniques at 128 facilities. Target volumes and dose constraints for spine, lung, and soft tissue were defined by the ACDS. Each plan was measured using Gafchromic EBT3 film and PTW 60019 microDiamond detector. A total of 782 plans were measured on 159 treatment machines of various classes and vendors. Audit results with the measured dose calculated as dose-to-medium, in medium (D) or dose-to-scaled density water, in water (D) were reported for all measurements, including those made in bone and lung equivalent materials.
The overall audit pass rate was 96% (271/281 plans) for the soft tissue case, 90% (215/238) for the spine, and 90% (236/263) for the lung. The average gamma pass rate for 5%/2mm criteria was 98.7% (soft tissue), 96.5% (spine), and 96.5% (lung). The average point dose difference was -1.0% (± 2.3%), 0.1% (± 3.8%), and -0.3% (± 3.2%) for the soft tissue, spine, and lung cases, respectively. The most common failure modes were in-target dose differences (41.6%) and Image Guided Radiation Therapy (IGRT) mismatches (36.7%).
High pass rates were seen for soft tissue, spine, and lung SBRT, indicating safe implementation of practice in the ANZ region. The modes of failure were assessed for suboptimal results, with the most frequent error due to IGRT mismatches, followed by dose differences in field, either underdosing or overdosing.
开展并实施全面的现场端到端剂量学审核,以评估澳大利亚和新西兰(澳新)放疗中心脊柱、肺部和软组织立体定向体部放疗(SBRT)的治疗准确性。
澳大利亚临床剂量测定服务(ACDS)拟人化胸部体模在128家机构按照当地技术进行了CT扫描、计划制定和治疗实施。ACDS定义了脊柱、肺部和软组织的靶区体积及剂量限制。每个计划均使用Gafchromic EBT3胶片和PTW 60019微型金刚石探测器进行测量。在159台不同类型和供应商的治疗机器上共测量了782个计划。所有测量结果均报告了以介质剂量(D)或水等效密度剂量(D)计算的测量剂量的审核结果,包括在骨等效材料和肺等效材料中进行的测量。
软组织病例的总体审核通过率为96%(271/281个计划),脊柱病例为90%(215/238),肺部病例为90%(236/263)。5%/2mm标准下的平均伽马通过率分别为软组织98.7%、脊柱96.5%、肺部96.5%。软组织、脊柱和肺部病例的平均点剂量差异分别为-1.0%(±2.3%)、0.1%(±3.8%)和-0.3%(±3.2%)。最常见的失败模式为靶区内剂量差异(41.6%)和图像引导放射治疗(IGRT)不匹配(36.7%)。
软组织、脊柱和肺部SBRT的通过率较高,表明在澳新地区该治疗方法的实施较为安全。对导致次优结果的失败模式进行了评估,最常见的误差是IGRT不匹配,其次是射野内剂量差异,包括剂量不足或剂量过量。